PE20040989A1 - Formulaciones que comprenden un compuesto de indolinona - Google Patents
Formulaciones que comprenden un compuesto de indolinonaInfo
- Publication number
- PE20040989A1 PE20040989A1 PE2003000913A PE2003000913A PE20040989A1 PE 20040989 A1 PE20040989 A1 PE 20040989A1 PE 2003000913 A PE2003000913 A PE 2003000913A PE 2003000913 A PE2003000913 A PE 2003000913A PE 20040989 A1 PE20040989 A1 PE 20040989A1
- Authority
- PE
- Peru
- Prior art keywords
- indolinone compound
- ilidenmetil
- carboxilico
- pirrol
- dihydroindol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UN COMPUESTO INDOLINONA DE FORMULA I DONDE R1 ES H, HALO, ALQUILO, CICLOALQUILO, ENTRE OTROS; R2 ES HALO, HIDROXI, ALCOXI, ENTRE OTROS; R3 ES H, ALQUILO, ARILO, HALOGENO, ENTRE OTROS; R4 ES H, HALOGENO, HIDROXI, ENTRE OTROS; R5 Y R6 SON CADA UNO H, ALQUILO, ENTRE OTROS; R7 ES H, ALQUILO, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (3-PIRROLIDIN-1-ILPROPIL)AMIDA DEL ACIDO 5-(5-BROMO-2-OXO-1,2-DIHIDROINDOL-3-ILIDENMETIL)-4-METIL-1H-PIRROL-2-CARBOXILICO; (2-DIETILAMINOETIL)METILAMIDA DEL ACIDO 5-(5-BROMO-2-OXO-1,2-DIHIDROINDOL-3-ILIDENMETIL)-1H-PIRROL-2-CARBOXILICO; ENTRE OTROS. SE REFIERE TAMBIEN A UNA FORMULACION SOLIDA DE ADMINISTRACION PARENTERAL U ORAL UTIL EN EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON PROTEINA QUINASA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42113302P | 2002-09-10 | 2002-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20040989A1 true PE20040989A1 (es) | 2004-12-28 |
Family
ID=31994326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003000913A PE20040989A1 (es) | 2002-09-10 | 2003-09-10 | Formulaciones que comprenden un compuesto de indolinona |
Country Status (31)
Country | Link |
---|---|
US (1) | US20040229930A1 (es) |
EP (1) | EP1536783B2 (es) |
JP (1) | JP2006503032A (es) |
KR (1) | KR20050059170A (es) |
CN (1) | CN1688304A (es) |
AR (1) | AR041193A1 (es) |
AT (1) | ATE403425T1 (es) |
AU (1) | AU2003280108B2 (es) |
BR (1) | BR0314182A (es) |
CA (1) | CA2498415C (es) |
DE (1) | DE60322720D1 (es) |
DK (1) | DK1536783T3 (es) |
DO (1) | DOP2003000708A (es) |
ES (1) | ES2309363T5 (es) |
GT (1) | GT200300193A (es) |
HN (1) | HN2003000272A (es) |
MX (1) | MXPA05002690A (es) |
MY (1) | MY136767A (es) |
NL (1) | NL1024261C (es) |
NO (1) | NO20051670L (es) |
NZ (1) | NZ538636A (es) |
PA (1) | PA8581801A1 (es) |
PE (1) | PE20040989A1 (es) |
PL (1) | PL375978A1 (es) |
PT (1) | PT1536783E (es) |
RU (1) | RU2005110663A (es) |
SI (1) | SI1536783T1 (es) |
TW (1) | TW200418836A (es) |
UY (1) | UY27969A1 (es) |
WO (1) | WO2004024127A2 (es) |
ZA (1) | ZA200501897B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2540639C (en) | 2003-10-02 | 2010-08-31 | Pharmacia & Upjohn Company Llc | Salts and polymorphs of a pyrrole-substituted indolinone compound |
EP1928462A1 (en) * | 2005-09-20 | 2008-06-11 | Pfizer Products Incorporated | Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
CN101007801A (zh) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | 吡咯取代的2-二氢吲哚酮衍生物、其制法与医药上的用途 |
WO2008024044A1 (en) * | 2006-08-21 | 2008-02-28 | Astrazeneca Ab | Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate |
TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
KR20100069705A (ko) * | 2007-11-21 | 2010-06-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 수니티닙 헤미-l-말레이트, 이의 다형 및 제조 방법, 라세미 수니티닙 말레이트의 다형, 수니티닙 염기 및 말산을 함유하는 조성물 및 이의 제조 방법 |
EP2113248A1 (en) | 2008-04-29 | 2009-11-04 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide |
EP2090306A1 (en) | 2008-02-13 | 2009-08-19 | Ratiopharm GmbH | Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
US20100310668A1 (en) * | 2008-02-13 | 2010-12-09 | Ratiopharm Gmbh | Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide |
EP2138167A1 (en) * | 2008-06-24 | 2009-12-30 | ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
WO2010011834A2 (en) | 2008-07-24 | 2010-01-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib and salts thereof and their polymorphs |
KR20100051769A (ko) * | 2008-09-30 | 2010-05-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 수니티닙 베이스 및 l-말산의 비정질 조성물 |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
CN103301116A (zh) * | 2012-03-16 | 2013-09-18 | 大鹏药品工业株式会社 | 口服医药组合物 |
EP3563865A3 (en) | 2012-05-04 | 2019-12-04 | Pfizer Inc | Prostate-associated antigens and vaccine-based immunotherapy regimens |
CN104069076A (zh) * | 2013-03-29 | 2014-10-01 | 浙江九洲药业股份有限公司 | 一种无定型的舒尼替尼与pvp的组合物 |
DK3062815T3 (en) | 2013-11-01 | 2019-03-11 | Pfizer | Vectors for expression of prostate-associated antigens |
WO2015110952A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof |
CN104829596B (zh) * | 2014-02-10 | 2017-02-01 | 石家庄以岭药业股份有限公司 | 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途 |
EP3539536A1 (en) | 2018-03-15 | 2019-09-18 | MH10 Spolka z ograniczona odpowiedzialnoscia | A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i |
CN114409630B (zh) * | 2019-01-09 | 2024-04-02 | 细胞基因公司 | 包含氧代异吲哚化合物的药物组合物以及使用它的方法 |
WO2022006512A1 (en) * | 2020-07-02 | 2022-01-06 | The Board Of Regents Of The University Of Texas System | Methods of treatment for melanoma |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4609675A (en) * | 1984-08-17 | 1986-09-02 | The Upjohn Company | Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing |
US6077533A (en) * | 1994-05-25 | 2000-06-20 | Purdue Pharma L.P. | Powder-layered oral dosage forms |
DK1233943T3 (da) * | 1999-11-24 | 2011-08-15 | Sugen Inc | Ioniserbare indolinon derivater og anvendelse deraf som PTK ligander |
DE19956598A1 (de) * | 1999-11-25 | 2001-06-13 | Bosch Gmbh Robert | Ventil zum Steuern von Flüssigkeiten |
EA005996B1 (ru) * | 2000-02-15 | 2005-08-25 | Сьюджен, Инк. | Пирролзамещенный 2-индолинон, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой |
CN100364991C (zh) * | 2001-08-15 | 2008-01-30 | 法玛西雅厄普约翰美国公司 | 2,4-二甲基-1h-吡咯-3-甲酰胺衍生物的苹果酸盐的晶体、其制备方法和其组合物 |
TWI259081B (en) * | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
-
2003
- 2003-09-09 TW TW092124905A patent/TW200418836A/zh unknown
- 2003-09-09 HN HN2003000272A patent/HN2003000272A/es unknown
- 2003-09-10 CN CNA038238500A patent/CN1688304A/zh active Pending
- 2003-09-10 KR KR1020057004142A patent/KR20050059170A/ko not_active Application Discontinuation
- 2003-09-10 MX MXPA05002690A patent/MXPA05002690A/es not_active Application Discontinuation
- 2003-09-10 DO DO2003000708A patent/DOP2003000708A/es unknown
- 2003-09-10 RU RU2005110663/15A patent/RU2005110663A/ru not_active Application Discontinuation
- 2003-09-10 AU AU2003280108A patent/AU2003280108B2/en not_active Ceased
- 2003-09-10 PT PT03772489T patent/PT1536783E/pt unknown
- 2003-09-10 PA PA20038581801A patent/PA8581801A1/es unknown
- 2003-09-10 UY UY27969A patent/UY27969A1/es not_active IP Right Cessation
- 2003-09-10 CA CA002498415A patent/CA2498415C/en not_active Expired - Lifetime
- 2003-09-10 PL PL03375978A patent/PL375978A1/xx not_active Application Discontinuation
- 2003-09-10 MY MYPI20033418A patent/MY136767A/en unknown
- 2003-09-10 DK DK03772489T patent/DK1536783T3/da active
- 2003-09-10 NL NL1024261A patent/NL1024261C/nl not_active IP Right Cessation
- 2003-09-10 BR BR0314182-9A patent/BR0314182A/pt not_active IP Right Cessation
- 2003-09-10 GT GT200300193A patent/GT200300193A/es unknown
- 2003-09-10 NZ NZ538636A patent/NZ538636A/en unknown
- 2003-09-10 DE DE60322720T patent/DE60322720D1/de not_active Expired - Lifetime
- 2003-09-10 EP EP03772489A patent/EP1536783B2/en not_active Expired - Lifetime
- 2003-09-10 SI SI200331328T patent/SI1536783T1/sl unknown
- 2003-09-10 JP JP2004535803A patent/JP2006503032A/ja active Pending
- 2003-09-10 ES ES03772489T patent/ES2309363T5/es not_active Expired - Lifetime
- 2003-09-10 AR ARP030103269A patent/AR041193A1/es not_active Application Discontinuation
- 2003-09-10 PE PE2003000913A patent/PE20040989A1/es not_active Application Discontinuation
- 2003-09-10 WO PCT/IB2003/005293 patent/WO2004024127A2/en active IP Right Grant
- 2003-09-10 US US10/658,801 patent/US20040229930A1/en not_active Abandoned
- 2003-09-10 AT AT03772489T patent/ATE403425T1/de not_active IP Right Cessation
-
2005
- 2005-03-04 ZA ZA200501897A patent/ZA200501897B/en unknown
- 2005-04-04 NO NO20051670A patent/NO20051670L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20040989A1 (es) | Formulaciones que comprenden un compuesto de indolinona | |
MXPA05009059A (es) | Derivados de heteroarilcarbamoilbenceno. | |
RU2437882C2 (ru) | Производные имидазолидинона | |
PE20070676A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo | |
PE20141228A1 (es) | Derivados de pirrolopirimidina y purina | |
PE20091095A1 (es) | Moduladores de gamma secretasa | |
PE20040687A1 (es) | Quinolinas sustituidas como antagonistas del receptor ccr5 | |
CY1105879T1 (el) | Αζαδικυκλο παραγωγα ως ανταγωνιστες μουσκαρινικου υποδοχεα | |
PE20040934A1 (es) | Derivados de pirimidina como inhibidores selectivos de tirosina quinasas | |
CA2682329A1 (en) | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | |
EA200970326A1 (ru) | Алкильные производные в качестве метаботропных рецепторов глутамата | |
PE20071171A1 (es) | Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropicos | |
PE20030940A1 (es) | Derivados de piridina y pirimidina | |
PE20070712A1 (es) | Sulfonamidas biciclicas como moduladores del receptor de glucocorticoides en el tratamiento de enfermedades inflamatorias | |
PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
ATE485044T1 (de) | Pyrimidin-verbindungen als purin- rezeptorantagonisten | |
PE20081800A1 (es) | NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA | |
PE20071177A1 (es) | Derivados de 3,5-piridina como inhibidores de renina | |
PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
PE20041078A1 (es) | Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh) | |
PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
PE20090984A1 (es) | Inhibidores de peptido desformilasa | |
PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
PE20061351A1 (es) | COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38 | |
PE20060498A1 (es) | Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa i(epsilon) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |